Background {#Sec1}
==========

Colorectal cancer (CRC) is the second most common cause of all cancer deaths in Europe and the Western world with a lifetime risk of approximately 5% \[[@CR1]\]. Despite the implementation of early detection programs about 20--25% of all patients have already synchronous metastases at the time of diagnosis and approximately 25--50% will develop metastases in the course of disease mainly in liver and lung \[[@CR2], [@CR3]\]. Liver metastases are the main cause of death and the only currently available curative therapy is the surgical R0 resection of metastases. Without any further treatment the median survival after metastases detection is poor with about 7.5 month \[[@CR4]\].

For patients with unresectable disease several systemic treatment options are available. In recent years prognosis has been improved with median survival rates in clinical trials of up to 30 months \[[@CR5]\]. The optimal treatment strategy is highly depending on the aim of the treatment, e.g. prolongation of survival, downsizing with secondary (potentially curative) resection, improving tumor-related symptoms, stopping tumor progression and/or maintaining quality of life, the side effect profile of the regimen, tumor -specific factors and comorbidities of the patient.

Combination chemotherapy regimens with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) provide higher response rates, longer progression-free survival (PFS) and better overall survival (OS) in first-line treatment compared to monotherapy regimens with 5-fluorouracil/leucovorin alone.

For patients with a good performance status and adequate organ function second-line chemotherapy should be offered. The chemotherapy regime in this situation is highly depending on the previous therapies, the therapy-free interval and pre-existing toxicities.

For patients who received an irinotecan-based regimen as first-line treatment the second-line treatment should consist of an oxaliplatin-containing combination (FOLFOX or capecitabine/oxaliplatin). For patients who received an oxaliplatin-based regimen as first-line treatment, the second-line treatment should be irinotecan-based (FOLFIRI or irinotecan alone) \[[@CR6], [@CR7]\].

The combination of conventional chemotherapy with molecular targeted therapies such as the anti-vascular endothelial growth factor (anti-VEGF) agents bevacizumab, ramucirumab and aflibercept or the anti-epidermal growth factor receptor (anti-EGFR) agents cetuximab and panitumumab should be considered depending on the tumor biology. After second-line chemotherapy many patients are still in a good condition to receive third-line treatment depending on the organ function and pre-existing toxicities.

Despite the recent improvements in CRC therapy there is still the need of developing new treatment strategies for patients with metastatic chemorefractory disease. One important pathway which is constitutively active in 90% of CRC is the canonical Wnt/β-catenin pathway \[[@CR8]\].

The S100 calcium binding protein A4 (S100A4) was identified as a Wnt/β-catenin target gene \[[@CR9]\]. S100A4, originally named metastasin 1 (MTS1), is associated with many physiological processes (e.g. migration, invasion, wound healing, neovascularisation). S100A4 is able to induce metastases in different experimental in vitro and animal models \[[@CR10]--[@CR13]\]. S100A4 is overexpressed in many different types of cancer \[[@CR14], [@CR15]\]. Its overexpression correlates with poor patients' prognosis; high S100A4 levels are prognostic for metachronous metastases formation and correlate with reduced patient survival in several cancer types \[[@CR16]--[@CR22]\]. However, S100A4 itself is not tumorigenic as shown by Ambartsumian et al. because transgenic mice with an overexpression of S100A4 do not develop tumors per se \[[@CR23]\].

In our own group we identified niclosamide as a transcriptional inhibitor of S100A4 expression by performing a high throughput screen for the human S100A4 promoter--driven reporter gene expression. Niclosamide is used since mid of the 1960s as an anti-helminthic drug which inhibits glucose uptake, oxidative phosphorylation and anaerobic metabolism \[[@CR24]\]. Niclosamide is approved by the Food and Drug Administration (FDA) and the European medicines agency (EMA) for treatment of tapeworm infections.

Consequently, we demonstrated the efficacy of niclosamide in cell culture by inhibition of S100A4-induced cell migration and invasion. We identified niclosamide as anti-metastatic drug in colon cancer xenografted mice by restriction of liver metastases linked to shorter survival. In this experimental setting, niclosamide interfered in the Wnt signaling pathway by disrupting the complexation of β-catenin/TCF with the S100A4 promoter leading to reduced expression of S100A4 \[[@CR13]\].

Other studies reported that niclosamide also interfered with the Wnt signaling pathways by inhibiting Wnt/Frizzled 1 signaling or by inducing the degradation of the Wnt co-receptor low density lipoprotein receptor-related protein 6 (LRP6) \[[@CR25], [@CR26]\]. Osada et al. demonstrated a niclosamide-induced decrease in Dvl2 expression, leading to reduced downstream β-catenin signaling \[[@CR27]\]. In hepatocellular cancer cells, niclosamide reduced cell proliferation, induced apoptosis, decreased TOP activity, and lowered β-catenin, Dvl2 and cyclin D1 levels \[[@CR28]\]. Ono et al. reported niclosamide-induced reduction of proliferation of primary human leiomyoma cells by inhibiting Wnt/β-catenin pathway activation, such as inhibited TOP activity, down-regulated pathway target genes e.g. Axin2, and reduced nuclear β-catenin translocation \[[@CR29]\]. Londoño-Joshi et al. demonstrated niclosamide-reduced levels of LRP6 and β-catenin for basal-like breast cancers \[[@CR30]\]. For ovarian cancer, niclosamide treatment resulted in increased cytotoxicity, reduction of Wnt/β-catenin signaling by TOP assay, and decreased Wnt pathway proteins e.g. Axin2 and cyclin D1 \[[@CR31]\]. King et al. demonstrated niclosamide-induced abrogation of Wnt7A/β-catenin signaling, inhibition of β-catenin transcriptional activity, cell viability, and decrease in cell migration \[[@CR32]\]. Satoh et al. showed that niclosamide inhibited cell proliferation, induced caspase-dependent apoptosis and G1 cell cycle arrest, and decreased cell migration, reduced the level of mediators of epithelial-to-mesenchymal transition, and decreased β-catenin expression, \[[@CR33]\]. Functionally, niclosamide is able to block further pathways besides Wnt/β-catenin signaling, known to be decisive for cancer initiation, progression and metastases \[[@CR34], [@CR35]\]. For instance, it inhibits the mTORC1 activity by lysosomal dysfunction in different cancer types \[[@CR36]--[@CR38]\], blocks the STAT3 phosphorylation and its translocation to the nucleus in prostate cancer cells \[[@CR39]\], and inhibits the NF-κB and Notch pathways \[[@CR40], [@CR41]\]. Thus, niclosamide has been reported as an anti-cancer molecule in numerous cancer types like CRC \[[@CR13]\], osteosarcoma \[[@CR42]\], breast cancer \[[@CR30], [@CR37]\], ovarian cancer \[[@CR31], [@CR43]\], prostate cancer \[[@CR44]\], non-small cell lung cancer (NSCLC) \[[@CR45], [@CR46]\], glioblastoma \[[@CR40]\], head and neck cancer \[[@CR47]\], multiple myeloma, and leukemia \[[@CR41], [@CR48]\].

Niclosamide has only little side effects and seems to be well tolerated even when applied over a long period \[[@CR49]\]. The oral dose of niclosamide for adults in anti-helminthic treatments is 2 g on day one followed by 1 g daily for 6 consecutive days. The serum concentration of niclosamide after a single dose of 2 g leads to maximal serum concentrations of 0.25--6.0 μg/ml which corresponds to the concentration used on the above mentioned models \[[@CR34], [@CR49]\].

As there is strong evidence from in vitro and in vivo experiments that niclosamide might be beneficial as anti-tumorigenic and anti-metastatic drug we designed the hereafter described clinical trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a CRC who progressed after therapy and for whom no other standard therapy is available.

Methods/Design {#Sec2}
==============

Study aims {#Sec3}
----------

This study evaluates the safety and efficacy of orally applied niclosamide in patients with metachronous or synchronous metastases of CRC origin, who progressed under previous therapy.

Study objectives {#Sec4}
----------------

Primary objective is PFS after 4 months. PFS after 4 months will be evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.

Secondary objectives are OS, time to progression, disease control rate (remission + partial remission + stable disease), and safety.

Pharmacokinetic analysis will be done to investigate niclosamide plasma concentration and a potential correlation with efficacy.

Study design {#Sec5}
------------

The study is a phase II single center, one-arm open-label clinical trial for patients with metastatic CRC.

Study schedule {#Sec6}
--------------

The trial has started on August 2015. The estimated accrual duration is 30 months. The estimated study completion date is 2018 (final data collection, date for primary outcome measure). Survival status will be collected for 2 years after registration.

Trial organization {#Sec7}
------------------

The trial is organised by the Charité Comprehensive Cancer Center (CCCC) in collaboration with the Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany.

Statistics {#Sec8}
----------

The study is a one-arm open-label clinical trial with interim analyses for futility of patients with metastatic CRC.

A Simon two-stage design will be used to allow early termination due to futility. The null hypothesis is that the probability of being free of progression (having stable disease, partial or complete response) at 4 months is p~0~ = 0.25 (H~0~: p \< =p~0~ = 0.25) estimated according to the recent literature \[[@CR50], [@CR51]\]. This null hypothesis will be tested with the Binomial test one-sided against the alternative H~1~ (estimated progression-free probability at 4 months of the experimental therapy) p1 = 0.5. Samples size for both stages were calculated according to the optimal design after Simon \[[@CR52]\].

In the first stage 17 patients will be recruited. If less than 5 of the first 17 patients are progression-free at 4 months the trial will be terminated prematurely. Otherwise 20 additional patients will be enrolled (up to a total of 37 patients).

The null hypothesis will be rejected if at least 13 patients out of 37 will be free of progression at 4 months. This design (optimal design after Simon) yields a type I error rate of 0.046 and a power of 0.902.

Analyses of PFS and OS survival will performed with Kaplan-Meier-curves, hazard ration will be reported with 95% confidence intervals. For safety analysis the worst toxicities in each cycle will be reported according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. A descriptive analysis of adverse events (AEs) and serious adverse events (SAEs) will be provided.

Recruitment process {#Sec9}
-------------------

The trial is expected to take up to 30 months to complete recruitment. Participants will be recruited from the Charité Universitätsmedizin Berlin. Following verbal and written study information in form of the patient information sheet and extensive discussion with a clinical trial physician, patients will get at least 24 h time to consider participation.

Patients who meet all the inclusion criteria and none of the exclusion criteria listed in Table [1](#Tab1){ref-type="table"} will be invited to provide written informed consent.Table 1Nikolo trial inclusion and exclusion criteria**Inclusion criteria** Disease related  Patients with metachronous or synchronous metastases of a colorectal cancer progressing under standard therapy  No proven brain metastases  No curative option available  No standard therapy available  At least one metastasis has to be measurable according to RECIST V 1.1 in X-ray computed tomography or magnetic resonance imaging (not older than 2 weeks before inclusion into the trial) Demographic  Age \> 18 years  Eastern Cooperative Oncology Group performance status ECOG 0--1 Laboratory  Absolute neutrophil count ≥ 1.5 × 10^9^/ L  Platelet count ≥ 100 × 10^9^/L  Leukocytes ≥ 1.0 × 10^9^/L  Hemoglobin ≥ 9.0 g/dL or 5.59 mmol/l  Bilirubin ≤ 2 x Upper Limit of Normal (ULN) if not due to Gilbert's syndrome  AST ≤ 2.5xULN in patients without liver metastases or ≤ 5.0xULN in patients with liver metastases  ALT ≤ 2.5xULN in patients without liver metastases or \< 5.0xULN in patients with liver metastases  Adequate renal function (creatinine ≤ 1.5xULN) Ethical/Other  Electrocardiography without clinical significant abnormalities  Written informed consent before inclusion according to the ICH-GCP and national/local regulations  Patients should use adequate birth control measures, during the study treatment period and for at least 3 months after the last study treatment  Women of childbearing potential need to have a negative pregnancy test 72 h before the application of the first dose of niclosamide  Patients who are breastfeeding must stop breastfeeding before the first dose of the study drug and not restart till 8 week after the last drug intake**Exclusion criteria** Concurrent conditions  Pregnant or lactating females  Other malignant disease (except colorectal cancer) within the last 5 years before inclusion in the trial except adequately treated basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ carcinoma of the cervix. Patients with a malignant disease in history have to be free of disease for 5 years  Clinical significant heart disease like e.g. uncontrolled blood pressure; heart failure NYHA grade \> 2; cardiac infarction within the last 12 months  Known uncontrolled concomitant disease despite treatment like e.g. chronic obstructive pulmonary disease  Known alcohol or drug abuse  Serious infection  Any psychological, familial, sociological or geographical condition, potentially hampering compliance with the study protocol and follow-up schedule Ethical/Other  Participation in another interventional study within the last 30 days  Known hypersensitivity against a part of the study drug  Life expectancy \< 3 months  Human immunodeficiency virus infection or active hepatitis B/C  Patients that are committed to an institution by official or judicial order  Persons that are depending on the sponsor, investigator or deputy

Study intervention and general considerations for dose modifications {#Sec10}
--------------------------------------------------------------------

Patients will start the treatment with the oral intake of 2 g niclosamide on day 1 and will continue with the medication once daily at the same time after a meal till disease progression or toxicity. Toxicities will be graded according to NCI CTCAE v4.03.

In case of an allergic reaction or vomiting ≥ grade II or diarrhoea or nausea or any other toxicity ≥ grade 3 the study medication will be paused until recovery and consequently reduced by one dose level (500 mg). If dose reductions to levels less than 1 g or discontinuation of the study treatment longer than 3 weeks are necessary, the study treatment will be terminated.

Assessments {#Sec11}
-----------

Patients will be followed up closely for side effects. This includes physical examinations as well as blood tests. Additional intensive analyses of niclosamide levels in the blood will be conducted in the first patient cohort (patients 1--5) in the first week to examine the absorption of niclosamide from the intestine and systemic circulation. To assess efficacy imaging will be performed every 2 months to evaluate the disease status.

Translational research {#Sec12}
----------------------

Patients will be asked to consent for optional translational research including analysis of patients' tumor tissue and additional blood analysis as described hereunder.

### Analysis of S100A4 expression in patient primary tumors and/or metastases or recurrent tumors {#Sec13}

If available, tumor tissue of the primary tumor and/or metastasis or recurrent tumor will be collected for patients who consent for optional translational research to do further analyses in specific subgroups (responder/non-responder). These tissues will be analyzed for S100A4 expression. These initial analyses characterizing the molecular starting point of the patient, depend on the availability of the amount of tissue procured for research purposes.

### Analysis of potential niclosamide-induced effects on circulating S100A4 transcripts in patient plasma {#Sec14}

The following initial analyses for characterization of the molecular starting point of the patient will be performed by using patients' plasma for determination of the basal levels of circulating S100A4 transcripts.

Peripheral blood samples will be collected at baseline and at end of treatment (due to progression, toxicity or other reasons) for all patients. For patients who consented for the optional translational research additional blood samples will be collected during routine blood taking at week 1, week 4 and thereafter monthly until progression. Blood samples will be used to discover and validate the prognostic and predictive value of S100A4 as well as for response to niclosamide and to evaluate relationship between other clinical outcome parameters.

### Plasma generation {#Sec15}

Immediately after every blood taking, plasma will be generated. Blood initially collected in EDTA tubes will be processed in the lab for generation of plasma aliquots (400 μl volume) which will be stored frozen at − 80 °C. Analysis will be performed after completion of collection of all samples.

Additional analyses of further circulating transcripts such as beta-catenin might follow in patients who consented for the optional translational research.

### Determination of niclosamide plasma concentration {#Sec16}

Plasma samples (400 μl) are supplemented with acetonitrile (800 μl) containing naproxen (0.25 μg/ml). The mixture is vortexed for 30 s and centrifuged at 15000 g for 20 min at room temperature. An aliqoute of 800 μl of supernatant is withdrawn and evaporated to dryness (N2, 50 °C). The samples were reconstituted in 400 μl dilution solvent consisting of acetonitrile/methanol/water (5%/5%/90%, *v*/v/v) and subjected to HPLC.

HPLC (Shimadzu) will be performed with Trentec Select columns (RP C8 120 ODS3 5 μm; 125 × 3,0 mm with guard column; mobile phase A: acetonitrile/water/phosphoric acid (70/30/0.1, *v*/v/v); mobile phase B: acetonitrile/water/phosphoric acid (25/75/0.1, v/v/v); gradient: 0.01 min B 70%; 8 min B 70%; 8.1 min B 0%; 25 min B 0%; 25.1 min B 70%; flow rate: 0.5 ml/min). Time of analysis is 50 min, injector volume is 100 μl, detection l ABS \[nm\] is performed at 250 nm.

HPLC calibration curves of naproxen and niclosamide are linear in the range of 0.05 to 1 μg/ml concentration of each analyte of a dilution series in dilution solvent (= acetonitrile/methanol/water (5%/5%/90%, v/v/v). The parameters of a linear regression equation are as follows, naproxen: R2 = 0.9999, y = 216,017×; niclosamide: R2 = 0.9937, y = 230,993× confirming a good linearity for both analytes.

Determination of niclosamide in human plasma samples is done by HPLC (BioTez GmbH, Berlin).

Discussion {#Sec17}
==========

Several research groups and our own studies could show that niclosamide inhibits crucial pathways associated with proliferation, migration and invasion like the Wnt/β-catenin pathway, leading to anti-cancer activity of the drug. Niclosamide is initially EMA- and FDA-approved for anti-helminthic treatment and has a good safety profile, which creates a solid basis for repositioning this drug for alternate uses. Our preclinical studies supported the strong potential of niclosamide as anti-cancer drug, which interferes with tumor progression and metastases formation via S100A4 inhibition. However, its application in cancer patients has not been investigated in patients yet. Therefore, the use of niclosamide represents a novel approach of particularly metastases intervention via inhibition of a defined molecular target, such as S100A4.

To better explore the therapeutic potential of niclosamide there is the need to conduct a clinical trial to investigate the safety, efficacy and pharmacokinetics of orally applied niclosamide in cancer patients, and most importantly, to investigate if niclosamide treatment will result in prolongation of the PFS of the patients. The attractiveness of this study is based on the fact that the drug activity in patients will be correlated with the molecular analysis of the target molecule S100A4 in patient's blood as the easiest accessible liquid biopsy for the timely monitoring. Furthermore, potential limiting factors, such as possible intra-individual difference in the drug absorption rate, will provide important additional information to what extend this will lead to variations of its anti-cancer efficacy.

As there is currently no predictive biomarker for response to niclosamide available we included an intense translational research program in our study to gain deeper insights in the mechanisms of niclosamide mediated anti-cancer activity. Thus, exploring the therapeutic potential of niclosamide in colon cancer patients in correlation to its target molecule S100A4 will enable us to evaluate this approach for broader uses in cancer therapy, where Wnt-signaling interference represents a rationale.
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